Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis. - Wikidata - awgldk - TriplyDB

Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis.

Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis.

http://www.wikidata.org/entity/Q41768874

about

Detection of DNA fusion junctions for BCR-ABL translocations by Anchored ChromPET Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia Issues in current management of chronic myeloid leukemia: Importance of molecular monitoring on long term outcome Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.Do we have to kill the last CML cell?Molecular genetic evaluation of myeloproliferative neoplasms.Present and future of molecular monitoring in chronic myeloid leukaemia.Current trends in molecular diagnostics of chronic myeloid leukemia.Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing.Minimal residual disease: the advantages of digital over analog polymerase chain reaction.gDNA Q-PCR for clinical monitoring of CML.Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for "personalized monitoring" of residual disease in chronic myeloid leukemia patients.gDNA qPCR is statistically more reliable than mRNA analysis in detecting leukemic cells to monitor CML.TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation.Authors' Reply to Crampe and Langabeer: Technical Issues Behind Molecular Monitoring in Chronic Myeloid Leukemia.Technical Issues Behind Molecular Monitoring in Chronic Myeloid Leukemia.

P2860

Q30432360-70ADDF8C-96A0-42FF-8C4A-515A4D1620B5 Q34781322-DD4D37C3-6631-431D-BB44-1105FA46A8F8 Q37422287-82CB28D8-E92F-43F2-B702-71FBE96A6277 Q37696776-FBB086BC-5147-4744-BCA9-BD2EC441E92E Q37789148-EF649E6A-30CB-4CBD-B282-B63AC083C2DA Q38481945-A050A9DA-9942-464E-B6FC-C6545491DA46 Q38762631-93A99FA6-DAB0-4A59-9169-3D02E993B972 Q38787015-E27412CE-827A-42A7-ADFF-E12E22E85873 Q39961918-B6F63B47-6BF8-4526-A2CD-07785A47B455 Q39984424-D242DA4D-47B7-4C9C-8B6C-2FF7ADF70F92 Q42910340-6E542000-A1EB-4E19-8C37-53EBBFD75441 Q52355106-435DDABA-30D1-40D3-9FBD-D0CB5AC92E37 Q54123354-CF76240A-A047-4989-AF42-E1451F20FEC3 Q54309446-431FADD5-DF2B-4D5D-B910-B19BECF0037D Q55052027-017ADD6E-BFCA-4E52-BF5A-C32018D1BAD8 Q55061759-055D92EA-7B48-4A37-B367-905A2270C408

P2860

Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis.

http://www.wikidata.org/entity/Q41768874

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Molecular monitoring of residu ...... th conventional mRNA analysis.

@en

type

label

Molecular monitoring of residu ...... th conventional mRNA analysis.

@en

prefLabel

Molecular monitoring of residu ...... th conventional mRNA analysis.

@en

P1433

Q41768874-3181F4CB-431C-4750-B8C0-9889C0BE5D2C

P1476

Q41768874-25721DB1-0805-4B78-BEBE-A9041972ACE3

P2093

Q41768874-48128F77-394B-4304-9259-46B52D0330C0

Q41768874-61A230C7-1E99-4306-BEBB-0B215EE1A323

Q41768874-6627FE41-C237-4B14-9CEA-2B46240FCDD3

Q41768874-A1552A02-E549-4850-9655-2D1816195EE7

Q41768874-A5E2183F-D397-4DDE-9F15-3D2A6A58CF00

Q41768874-C231B662-B287-4BC2-A1E4-E49DA4FEE4FC

Q41768874-C8D08E14-2BA0-4437-8917-A1B2C474C2EF

P2860

Q41768874-0AEE983F-8F86-438A-B77E-ED3C813691A0

Q41768874-0D92A7E9-7CA0-463A-BD7E-4C57E5835F48

Q41768874-10F41DD3-7F33-4054-B545-304287E56714

Q41768874-1CCAE213-A9AE-4F7A-B189-ADB85D6CAF47

Q41768874-281AF292-5343-4654-90B0-7BEF98534F07

Q41768874-2EE11189-48F6-4F74-9F0F-B4A0769807B0

Q41768874-316682CE-0C2A-42C8-A257-2A5744245B84

Q41768874-432B88D3-5732-42BC-8EAA-1C8F0B6A7358

Q41768874-845599A6-8083-4E81-B5E2-8A8605153C47

Q41768874-8F9B5A20-17C5-43FC-8071-0849A310EACE

P304

Q41768874-EC9B1D59-4919-4B97-A6D3-BCB8FF3CC17A

P31

Q41768874-5F20579F-AD53-4E0D-B28D-89DB255B63BC

P356

Q41768874-5CAF2516-AB0A-4F0D-BC00-EBD860A99259

P433

Q41768874-4757261F-8D32-463C-A9F3-81D55183154A

P478

Q41768874-3405FB8A-45BB-40EF-8F77-E88835012031

P577

Q41768874-0C5DC116-1BD0-400D-ACCE-54BC44B593D1

P5875

Q41768874-065C7196-69C2-4939-8FAE-06E567614DCA

P698

Q41768874-B28E23C0-F1A9-4B80-B73D-7280E2BFB69D

P921

Q41768874-DD7BCBB9-01B0-45BB-8FD4-8D1FA4B728D9

P932

Q41768874-31155B24-DB81-4ED5-A0F3-44092AB710BE

P356

JMOLDX.2009.080150

P1433

The Journal of Molecular Diagnostics

P1476

Molecular monitoring of residu ...... th conventional mRNA analysis.

@en

P2093

Alessandro Rambaldi

http://www.w3.org/2001/XMLSchema#string

Elia Mattarucchi

http://www.w3.org/2001/XMLSchema#string

Francesco Lo Curto

http://www.w3.org/2001/XMLSchema#string

Francesco Pasquali

http://www.w3.org/2001/XMLSchema#string

Giovanni Porta

http://www.w3.org/2001/XMLSchema#string

Leonardo Campiotti

http://www.w3.org/2001/XMLSchema#string

Orietta Spinelli

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Chronic myeloid leukaemia as a model of disease evolution in human cancer.

Practical management of patients with chronic myeloid leukemia receiving imatinib.

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia.

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Punish the parent not the progeny.

Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era.

Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?

P304

482-487

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2353/JMOLDX.2009.080150

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26770384

http://www.w3.org/2001/XMLSchema#string

P698

19710400

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

P932

2729847

http://www.w3.org/2001/XMLSchema#string